Scilex Holding Co
Scilex Holding Company (Nasdaq: SCLX) develops and commercializes non-opioid pain treatments, with products for neuropathic pain, migraine and gout and candidates in development for sciatica, acute pain and fibromyalgia. Its commercial products are ZTlido, a prescription lidocaine topical system for postherpetic… From the company’s description.
Over the twelve months to Jun 30, 2026, Scilex Holding Co reported revenue of $31.61M, down 28.5% from a year earlier, and a net loss of $464.56M. Operations used $17.09M in cash. In fiscal 2025, it reported revenue of $30.25M, down 46.5% from fiscal 2024, and a net loss of $374.05M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Scilex Holding Co does
In the company’s own words
Scilex Holding Company (Nasdaq: SCLX) develops and commercializes non-opioid pain treatments, with products for neuropathic pain, migraine and gout and candidates in development for sciatica, acute pain and fibromyalgia. Its commercial products are ZTlido, a prescription lidocaine topical system for postherpetic neuralgia; ELYXYB, an oral solution for acute migraine in adults; and GLOPERBA, liquid colchicine for preventing gout flares in adults. Product candidates include SEMDEXA, SP-103 and SP-104; the company also holds a license to develop and commercialize KDS2010 for metabolic and neurodegenerative diseases. Scilex sells through a U.S. commercial organization that reaches healthcare providers, payers, wholesalers and pharmacies. It reports one business focused on acquiring, developing and commercializing pharmaceutical products, alongside a treasury strategy centered on cryptocurrency holdings. Scilex was formed as a public company through a 2022 business combination between Vickers Vantage Corp. I and Legacy Scilex. Its website is www.scilexholding.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1820190
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Scilex Holding Co — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Scilex Holding Co’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Scilex Holding Co and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Scilex Holding Co's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Scilex Holding Co's last four quarterly filings that the numbers alone won't show?”